Vyome Therapeutics Announces New Board with AI and MIT Ties Ahead of Public Listing

Vyome Therapeutics has announced a new Board of Directors, consisting of MIT alumni with expertise in AI and business, as it prepares for a public listing under the new name Vyome Holdings. The company will take over ReShape Lifesciences on August 15, 2025, and trade on the Nasdaq under the ticker symbol 'HIND'. The new board emphasizes shareholder interests and aims to leverage clinical-stage assets for transformative healthcare solutions.

Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases, has announced the composition of its new Board of Directors as it prepares for a public listing on August 15, 2025. The new board will take control of ReShape Lifesciences (NASDAQ: RSLS), which will be renamed Vyome Holdings, Inc. and trade under the ticker symbol HIND [1].

The new board includes four members with ties to the Massachusetts Institute of Technology (MIT) and extensive experience in AI and business. The board members are:

- Krishna Gupta (Chairman), MIT engineering/business alum and CEO of Remus Capital, focused on Vertical AI applications in healthcare.
- Shiladitya Sengupta (Founder), MIT postgrad and serial entrepreneur, with a focus on medicine and engineering.
- Venkat Nelabhotla (Co-founder and CEO), IIM Ahmedabad alum, with 30+ years of experience in pharma, biotech, and CPG industries.
- Mohanjit Jolly (Shareholder), MIT alum and Partner of Iron Pillar, a seasoned investor with a focus on cutting-edge technology companies.
- John Tincoff (Shareholder), Georgetown alum and Partner at Remus Capital, with a focus on industrial applications and governance.
- Stash Pomichter (Shareholder), MIT engineering dropout and member of the Remus Capital team, with a focus on cutting-edge AI applications.

The new board emphasizes shareholder interests and aims to leverage Vyome's clinical-stage assets for transformative healthcare solutions. The company plans to trade on the Nasdaq under the ticker symbol HIND, following the merger with ReShape Lifesciences [2].

References:

[1] https://www.morningstar.com/news/business-wire/20250812232598/vyome-announces-new-board-of-directors-with-deep-mit-and-ai-ties
[2] https://www.biospace.com/press-releases/reshape-lifesciences-announces-shareholder-approval-of-merger-with-vyome-therapeutics